Molecure SA
WSE:MOC
Gross Margin
Molecure SA
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| PL |
M
|
Molecure SA
WSE:MOC
|
183.8m PLN |
-444%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
779.4B USD |
81%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
394B USD |
69%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.1T DKK |
85%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
236.5B CHF |
73%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
177B GBP |
82%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
225.9B USD |
81%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
199.7B CHF |
75%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
167.6B USD |
68%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
142.8B USD |
74%
|
Molecure SA
Glance View
Molecure SA engages in the discovery and development of small molecules for the treatment of unmet medical needs. The company is headquartered in Warsaw, Woj. Mazowieckie and currently employs 106 full-time employees. The company went IPO on 2018-04-19. The firm is dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The firm's business model is focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations in specific disease areas. The firm has a platform of 3 distinct small molecule programs targeting chitinases hydrolytic enzymes with potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need. Additionally, it has initiated a program focused on development of small molecule immune modulators to stop the ability of tumors to escape immune surveillance.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Molecure SA's most recent financial statements, the company has Gross Margin of -444%.
You don't have any saved screeners yet